[{"orgOrder":0,"company":"J-Star Research","sponsor":"MetasTx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"IPA-3","moa":"PAK1","graph1":"Oncology","graph2":"Preclinical","graph3":"J-Star Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"J-Star Research \/ J-STAR Research","highestDevelopmentStatusID":"4","companyTruncated":"J-Star Research \/ J-STAR Research"}]

Find Clinical Drug Pipeline Developments & Deals by J-Star Research

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The stability and efficacy of MTX-101 (IPA-3), are significantly superior in inhibiting prostate tumor growth and metastasis in various mouse models of prostate cancer and demonstrate broad applicability across solid tumor cancers.

                          Brand Name : MTX-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 07, 2022

                          Lead Product(s) : IPA-3

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : MetasTx

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank